GlaxoSmithKline Pharma stock (INE159A01016): Q4 profit rises 6% YoY

GlaxoSmithKline Pharmaceuticals reported a 5.7% increase in Q4 FY26 consolidated net profit to Rs 277.86 crore, with shares gaining 1.65% to Rs 2,446.60. Full-year PAT hit Rs 1,012 crore, up 10%.

GlaxoSmithKline Pharmaceuticals Ltd (GSK Pharma) announced its Q4 and full-year FY26 results on May 13, 2026, showing consolidated net profit up 5.7% year-over-year to Rs 277.86 crore for the quarter ended March 31, 2026, from Rs 262.87 crore prior year, according to a Rediff Money report as of 05/13/2026. Revenue from operations rose 2.15% to Rs 995.30 crore. The stock advanced 1.65% to Rs 2,446.60 on the news, per Business Standard as of 05/14/2026. Standalone PAT increased 5.68% to Rs 274.94 crore on 2.38% revenue growth to Rs 989.15 crore.

As of: 14.05.2026

By the editorial team – specialized in equity coverage.

At a glance

• Name: GlaxoSmithKline Pharmaceuticals Ltd
• Sector/industry: Pharmaceuticals
• Headquarters/country: India
• Core markets: India, with global ties
• Key revenue drivers: Innovative therapies, established drugs
• Home exchange/listing venue: BSE/NSE (500660)
• Trading currency: INR

GlaxoSmithKline Pharma: core business model

GlaxoSmithKline Pharmaceuticals Ltd, known as GSK Pharma, operates as the Indian subsidiary of global pharma giant GSK plc. It focuses on manufacturing and marketing branded pharmaceuticals, vaccines, and consumer healthcare products primarily in India. The company leverages its parent's R&D capabilities while tailoring offerings to local needs, emphasizing respiratory, dermatology, and general medicine segments, as detailed in its Q4 FY26 press release as of 05/13/2026.

GSK Pharma's model combines established generics and patented innovative therapies, with recent emphasis on AI-optimized field productivity and cost discipline driving margins. Full-year FY26 revenue reached INR 3,790 crore, up 2%, underscoring steady demand in India's pharma market.

Main revenue and product drivers for GlaxoSmithKline Pharma

Key drivers include its innovative portfolio in vaccines and specialty medicines, alongside pricing strategies and field force enhancements. Q4 EBITDA rose 3.48% to Rs 386.88 crore, reflecting improved profitability published for the period ended March 31, 2026, per Moneycontrol as of 05/13/2026. The board recommended a final dividend of Rs 57 per share for FY26.

Full-year PAT grew 10% to Rs 1,012 crore, supported by stable pharma demand and asset-sale gains, making it relevant for US investors tracking emerging market pharma plays with ADRs or global exposure.

Industry trends and competitive position

India's pharma sector benefits from rising healthcare spend and exports, where GSK Pharma holds a solid position via brands like Augmentin and Calpol. Its focus on innovation aligns with trends toward specialty drugs amid generic competition.

Why GlaxoSmithKline Pharma matters for US investors

US investors may eye GSK Pharma for diversification into India's fast-growing pharma market, indirectly linked via parent GSK plc (NYSE: GSK). Its consistent profitability and dividend track record offer exposure to Asia-Pacific growth without direct US listing risks.

Conclusion

GlaxoSmithKline Pharma delivered solid Q4 FY26 results with profit growth and margin expansion, alongside a proposed dividend. Full-year performance highlights resilience in a competitive market. Investors monitor ongoing innovation and India pharma dynamics for future updates.

Disclaimer: This article does not constitute investment advice. Stocks are volatile financial instruments.